ErbB receptors: Possible therapeutic targets in prostate cancer?

BJU International

Volumn 92, Issue 9, 2003, Pages 890-895

  Ratan, H L ^a   Gescher, A ^a   Steward, W P ^a   Mellon, J K ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

EGFR; HER 2; Prostatic neoplasms

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANDROGEN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; MITOGENIC AGENT; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TYRPHOSTIN;

ACNE; ADVANCED CANCER; ANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL PATHWAY; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RASH; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0346119093     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04503.x     Document Type: Short Survey

References (32)

1. Cohen D, Simak R, Fair W, Melamed J, Scher H, Cordon-Cardo C. Expression of transforming growth factor-α and the epidermal growth factor receptor in human prostate tissues. J Urol 1994; 152: 2120-4
2. Kim H-G, Kassis J, Souto J, Turner T, Wells A. EGF receptor signalling in prostate morphogenesis and tumorigenesis. Histol Histopathol 1999; 14: 1175-82
3. Kumar VL, Majumder P, Gujral S, Kumar V. Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. Cancer Lett 1998; 134: 177-80
4. Mellon K, Thompson S, Charlton R, Marsh C, Robinson M, Lane D. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992; 147: 496-9
5. Glynne-Jones E, Goddard L, Harper ME. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 1996; 27: 688-94
6. Olapade-Olaopa E, Moscatello D, MacKay E, Horsburgh T, Sandhu D, Terry T. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000; 82: 186-94
7. Seth D, Shaw K, Jazayeri J, Leedman P. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells. Br J Cancer 1999; 80: 657-69
8. Harper M, Goddard L, Glynne-Jones E. An immuno-cytochemical analysis of TGF-α expression in benign and malignant prostatic tumours. Prostate 1993; 23: 9-23
9. Leav I, McNeal J, Ziar J, Alroy J. The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic and carcinomatous lesions. Human Pathol 1998; 29: 668-75
10. Ilio KY, Sensibar JA, Lee C. Effect of TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl 1995; 16: 482-90
11. Lee C, Sintich SM, Mathews EP et al. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999; 39: 285-90
12. Iwamura M, Hoshiba K, Cockett A. Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate Supplement 1998; 8: 14-7
13. Schuurmans A, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumour cell. Prostate 1988; 12: 55-63
14. Schuurmans AL, Bolt J, Mulder E. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol Cell Endocrinol 1988; 60: 101-4
15. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45
16. Di Lorenzo G, Tortora G, D'Armiento FP et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44
17. Jenster G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 2000; 191: 227-8
18. Sherwood E, Van Dongen J, Wood C, Liao S, Kozlowski J, Lee C. Epiderma growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77: 855-61
19. Jones H, Barrow D, Dutkowski C et al. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways. Prostate 2001; 49: 38-47
20. Slamon D, Clark G, Wong S. Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82
21. Craft N, Shostak Y, Carey M, Sawyers C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280-5
22. Ross J, Sheehan C, Hayner-Buchan A, Ambros R, Kallakury B, Kaufman R. Prognostic significance of Her-2/neu ocogene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162-70
23. Signoretti S, Montironi J, Altimari A, Tam C, Bubley G, Balk S. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25
24. Shi Y, Brands F, Chatterjee S, Feng A-C, Groshen S, Schewe J. HER-2/Neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001; 166: 1514-9
25. Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58 (Suppl. 2A): 114-22
26. Slovin S, Kelly W, Cohen R. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen independent (Al) prostate cancer (PC): results of a phase Ib/II study [abstract]. Proc Am Soc Clin Oncol 1997; 16: A1108
27. Agus D, Scher H, Higgins B. Response of prostate cancer to anti-HER-2/ neu antibody in androgen-dependent and independent human xenograft models. Cancer Res 1999; 59: 4761-4
28. Schmidt M, Reiser P, Hills D, Gullick W, Wels W. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-Receptor-specific antibody-toxin. Int J Cancer 1998; 75: 878-84
29. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63
30. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dua ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002; 62: 5254-9
31. Han Y, Caday C, Nanda A. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncate rather than wild-type epidermal growth factor receptors. Cancer Res 1996; 56: 3859-61
32. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth Find Exp Clin Pharmacol 1998; 20: 825-31